View ValuationBiomark Diagnostics 将来の成長Future 基準チェック /06現在、 Biomark Diagnosticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 24Biomark Diagnostics Secures Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood TestBioMark Diagnostics Inc. has officially received formal patent allowances from both the Canadian Intellectual Property Office (CIPO) and the European Patent Office (EPO) for its groundbreaking lung cancer early detection technology. BioMark's minimally invasive blood test leverages a newly patented algorithm designed to boost screening rates and catch non-small cell lung cancer (NSCLC) at its earliest, most treatable stages. The clinical validation of BioMark's metabolomics platform is anchored in exceptionally robust data, having already shown immense promise across more than 15,000 blood samples collected throughout Quebec, France, and Germany. The simultaneous allowances from both CIPO and the EPO represent a profound validation of the scientific approach and the clinical significance of the metabolomics platform. These are not peripheral claims; they protect the core metabolic signatures and advanced algorithms driving the screening panel. This vast multi-jurisdictional clinical asset underscores the reliability, reproducibility, and potential of the platform across diverse population groups. BioMark continues to advance corresponding patent applications actively under prosecution in additional major markets, including the United States, China, and Japan, while preparing for the upcoming commercial launch later this year. The dual validation from Canadian and European patent authorities reinforces the scientific novelty, capturing the attention of international stakeholders looking at the latest diagnostic advancements. By securing this solid intellectual property foundation, BioMark is uniquely positioned to accelerate international commercial partnerships, licensing agreements, and engagement with global health systems looking to integrate cutting-edge diagnostics.お知らせ • Jan 16Biomark Diagnostics Inc. Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in OncologyBioMark Diagnostics Inc. announced that its long-term investment in integrating artificial intelligence and machine learning into metabolomic profiling has achieved a major milestone. As the global healthcare investment community is focused on the transformative power of AI at the J.P. Morgan Healthcare Conference, BioMark has received this week notification that its research regarding a machine learning-driven predictive model for lung cancer detection has been accepted for publication in the prestigious, peer-reviewed journal Frontiers in Oncology. The accepted article, titled "Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection," represents a successful realization of BioMark's strategy to utilize advanced computational tools to enhance diagnostic precision. This achievement validates the company's past capital allocation toward sophisticated AI infrastructure and confirms the scientific rigor of its metabolic pathway analysis. By moving beyond traditional biomarker identification and utilizing pathway-level data, BioMark has demonstrated a more comprehensive way to interpret the metabolic signatures of early-stage lung cancer. This research was made possible through a strategic collaboration with Dr. Maria Vaida and her team at the Harrisburg University of Science and Technology. The publication describes the use of pathway-based features from the Human Metabolome Database (HMDB) and explores the mechanistic drivers of cancer through interpretability tools such as SHAP analysis. This methodological approach allows for a deeper understanding of how specific metabolic pathways, such as those involved in nutrient processing and tumor growth, contribute to diagnostic models. The partnership with Harrisburg University has been instrumental in bridging the gap between complex data science and clinical application, ensuring that BioMark's technological foundation is built upon peer-reviewed, world-class scientific inquiry.お知らせ • Jan 01Biomark Diagnostics Inc. Appoints James Lavender as Board of Director, Effective December 22, 2025BioMark Diagnostics Inc. has appointed Mr. James Lavender to its Board of Directors following resolutions from the Annual General Meeting held on December 22, 2025. Mr. Lavender and his group were major investors in BioMark's most recent financing, completed in March 2025, underscoring strong insider alignment with the Company's growth strategy as it transitions from development to commercial execution. As BioMark accelerates its U.S. market entry, Mr. Lavender has been instrumental in opening high-level channels with state-level organizations and strategic investment groups across the United States. Mr. Lavender brings extensive software development and enterprise sales experience from leading technology companies, with a particular focus on scaling data-driven platforms. He has been a key advocate for expanding BioMark's use of Artificial Intelligence (AI) and Machine Learning (ML) to enhance clinical performance, automation, and scalability of metabolomics-based oncology diagnostics.お知らせ • Oct 14Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025.お知らせ • May 12Biomark Diagnostics Inc. Announces the Publication of Pivotal Study as Part of the Special Issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular SciencesBioMark Diagnostics Inc. announced the publication of a pivotal study as part of the special issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular Sciences. The research, titled "Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection", provides significant external validation for BioMark's metabolomics and machine learning powered technology, particularly highlighting its high specificity and accuracy in detecting early-stage non-small cell lung cancer (NSCLC) and differentiating it from other non-cancerous lung conditions. The study utilized a large, clinically diverse patient cohort, analyzing 680 archived plasma samples in a discovery cohort and an independent set of 216 plasma samples for validation. A key strength of the research was the composition of the control group, which included not only healthy individuals but also patients with various non-cancerous lung diseases. This design allowed for a rigorous assessment of the test's ability to accurately identify lung cancer, minimizing the potential for false positives due to other lung conditions. The ability to detect lung cancer at its earliest stages significantly improves patient outcomes and survival rates. Current screening methods, such as low dose computed tomography (LDCT), have limitations, including lower sensitivity and specificity compared to regular CT scans, and can result in false positives leading to unnecessary invasive procedures. BioMark's minimally invasive blood test offers a promising approach to complement current screening methods, potentially leading to earlier interventions and better patient prognoses.お知らせ • Mar 31Biomark Diagnostics Inc. announced that it has received CAD 4.261195 million in fundingOn March 31, 2025, BioMark Diagnostics Inc. closed the transaction. The company announced that it has issued 4,593,984 units at an issue price of CAD 0.30 per unit for gross proceeds of CAD 1,378,195.2 in second and final tranche. The Units were issued at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 4,261,195. Each unit consists of one common share and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. Certain Insiders, Directors and Officers subscribed for a portion of this placement. Participation of the insiders of the Company in the private placement. The transaction included participation from United States and Europe. The transaction is oversubscribed.お知らせ • Mar 27Biomark Diagnostics Inc. announced a financing transactionBiomark Diagnostics Inc. announced a non-brokered private placement that it will issue units to receive funding on March 26, 2025. Each unit consists of one common share of company and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. No finders' fees were payable on the private placement. Under the first tranche, the company issued 9,610,000 units at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 2,883,000.お知らせ • Oct 21Biomark Diagnostics Inc., Annual General Meeting, Dec 27, 2024Biomark Diagnostics Inc., Annual General Meeting, Dec 27, 2024. Location: british columbia, richmond Canadaお知らせ • Sep 10Biomark Diagnostics Completes Testing of over 5,400 Subjects as Part of A Validation Study for Early Lung Cancer DetectionBioMark Diagnostics Inc. announced the successful completion of a significant clinical trial in collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Quebec. Over 5,400 patient samples were analyzed using BioMark's innovative lung cancer assay, demonstrating the test's potential to revolutionize early detection and improve patient outcomes. BioMark has partnered with a leading data analytics group possessing robust artificial intelligence and machine learning capabilities to analyze the vast amount of data collected during the trial. The results of the study will be presented at an upcoming medical conference and submitted for publication in a peer-reviewed journal. BioMark is committed to advancing the development of its lung cancer assay and making it available to patients in need as soon as possible. This innovative technology has the potential to significantly improve early detection rates and treatment outcomes for this devastating disease.お知らせ • Dec 29Biomark Diagnostics Inc. announced that it has received CAD 1.9 million in fundingBiomark Diagnostics Inc announced that it has completed a non-brokered private placement of 7,600,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 1,900,000 on December 29, 2023. The securities issued under the private placement will be subject to a hold period of four months and one day. Each unit consists of one common share and one-full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.45 per share for a period of three years from the closing date of the private placement, subject to an acceleration clause. Certain Insiders, Directors and Officers subscribed for a portion of this placement. No Finders' fees were payable on the private placement.お知らせ • Oct 13Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2023Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2023.お知らせ • Jan 12BioMark Diagnostics Inc. Announces Update from Ongoing Clinical Trial Using its Lung Cancer Liquid Biopsy Test as it Prepares for Commercial LaunchBioMark Diagnostics Inc. announced several updates from ongoing clinical trial using the Company's liquid biopsy test for early cancer detection and monitoring of lung cancer. As clinical trial success relies on effective patient recruitment, BioMark is delighted to announce that enrollment for its pivotal lung cancer screening study exceeded 1,000 participants in less than one year. The lung cancer screening demonstration project led by Dr. Simon Martel, pulmonologist at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie de Québec- Université Laval - IUCPQ-UL), is intended to combine BioMark's metabolomics liquid biopsy test with radiomics and genetics biomarkers to help at-risk Quebecers get access to an accurate and accessible lung cancer screening program. The multimodal study was designed to recruit 4,000 participants from eight major hospitals across in Quebec, generating data that can support BioMark's implementation within the Province of Quebec. The Company also announces its first international patient recruited as part of a European prospective lung cancer screening trial in France known as the ILYAD study. BioMark's blood-based biomarker panel has been selected to define personalized lung cancer risk assessment in Europe's screen-eligible population who are most likely to benefit from a CT scan. The study is being conducted by Pr Sébastien Couraud, pulmonologist at the Hospices Civils de Lyon (HCL) and through a partnership with France- based TransDiag. Through the ILYAD study, the investigators are studying the participation rate during the initial round in the lung cancer screening program and assessing the performance of several blood- based biomarkers for the detection of cancers in screened individuals. The test being developed by the consortium would offer the opportunity to screen nearly 4 million individuals in France who are eligible for lung cancer screening under current European guidelines. These at-risk individuals are aged between 50 and 75 and have a history of heavy smoking. The Company intends to pursue clinical validation of the test as a laboratory developed test (LDT) in parallel with these ongoing studies. The BioMark Lung Cancer Risk Assessment Test will be available through its Quebec-based accredited laboratory, BioMark Diagnostic Solutions Inc., within approximately 9 - 12 months based on the completion of the ISO 15-189 certification. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Biomark Diagnostics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:BMKD.F - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20250-2-2-1N/A9/30/20250-2-1-1N/A6/30/20250-2-1-1N/A3/31/20250-2-1-1N/A12/31/20240-2-1-1N/A9/30/20240-2-1-1N/A6/30/20240-2-1-1N/A3/31/20240-1-1-1N/A12/31/20230-2-1-1N/A9/30/20230-2-1-1N/A6/30/20230-2-1-1N/A3/31/20230-2-1-1N/A12/31/20220-2-1-1N/A9/30/20220-2-1-1N/A6/30/20220-2-1-1N/A3/31/20220-1-1-1N/A12/31/20210-1-1-1N/A9/30/2021N/A-1-1-1N/A6/30/2021N/A-1-1-1N/A3/31/2021N/A-1-1-1N/A12/31/2020N/A-1-1-1N/A9/30/20200-1-1-1N/A6/30/20200-1-1-1N/A3/31/20200-100N/A12/31/20190-100N/A9/30/2019N/A-1N/A0N/A6/30/2019N/A-1N/A0N/A3/31/2019N/A-1N/A0N/A12/31/2018N/A-1N/A-1N/A9/30/2018N/A-1N/A-1N/A6/30/2018N/A-1N/A-1N/A3/31/2018N/A-1N/A-1N/A12/31/2017N/A-1N/A0N/A9/30/2017N/A-1N/A0N/A6/30/2017N/A-1N/A0N/A3/31/2017N/A-1N/A0N/A12/31/20160-1N/A-1N/A9/30/20160-1N/A0N/A6/30/2016N/A-1N/A0N/A3/31/2016N/A-1N/A0N/A12/31/20150-1N/A-1N/A9/30/20150-3N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BMKD.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BMKD.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BMKD.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BMKD.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BMKD.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BMKD.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/05 20:01終値2026/07/02 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biomark Diagnostics Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 24Biomark Diagnostics Secures Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood TestBioMark Diagnostics Inc. has officially received formal patent allowances from both the Canadian Intellectual Property Office (CIPO) and the European Patent Office (EPO) for its groundbreaking lung cancer early detection technology. BioMark's minimally invasive blood test leverages a newly patented algorithm designed to boost screening rates and catch non-small cell lung cancer (NSCLC) at its earliest, most treatable stages. The clinical validation of BioMark's metabolomics platform is anchored in exceptionally robust data, having already shown immense promise across more than 15,000 blood samples collected throughout Quebec, France, and Germany. The simultaneous allowances from both CIPO and the EPO represent a profound validation of the scientific approach and the clinical significance of the metabolomics platform. These are not peripheral claims; they protect the core metabolic signatures and advanced algorithms driving the screening panel. This vast multi-jurisdictional clinical asset underscores the reliability, reproducibility, and potential of the platform across diverse population groups. BioMark continues to advance corresponding patent applications actively under prosecution in additional major markets, including the United States, China, and Japan, while preparing for the upcoming commercial launch later this year. The dual validation from Canadian and European patent authorities reinforces the scientific novelty, capturing the attention of international stakeholders looking at the latest diagnostic advancements. By securing this solid intellectual property foundation, BioMark is uniquely positioned to accelerate international commercial partnerships, licensing agreements, and engagement with global health systems looking to integrate cutting-edge diagnostics.
お知らせ • Jan 16Biomark Diagnostics Inc. Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in OncologyBioMark Diagnostics Inc. announced that its long-term investment in integrating artificial intelligence and machine learning into metabolomic profiling has achieved a major milestone. As the global healthcare investment community is focused on the transformative power of AI at the J.P. Morgan Healthcare Conference, BioMark has received this week notification that its research regarding a machine learning-driven predictive model for lung cancer detection has been accepted for publication in the prestigious, peer-reviewed journal Frontiers in Oncology. The accepted article, titled "Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection," represents a successful realization of BioMark's strategy to utilize advanced computational tools to enhance diagnostic precision. This achievement validates the company's past capital allocation toward sophisticated AI infrastructure and confirms the scientific rigor of its metabolic pathway analysis. By moving beyond traditional biomarker identification and utilizing pathway-level data, BioMark has demonstrated a more comprehensive way to interpret the metabolic signatures of early-stage lung cancer. This research was made possible through a strategic collaboration with Dr. Maria Vaida and her team at the Harrisburg University of Science and Technology. The publication describes the use of pathway-based features from the Human Metabolome Database (HMDB) and explores the mechanistic drivers of cancer through interpretability tools such as SHAP analysis. This methodological approach allows for a deeper understanding of how specific metabolic pathways, such as those involved in nutrient processing and tumor growth, contribute to diagnostic models. The partnership with Harrisburg University has been instrumental in bridging the gap between complex data science and clinical application, ensuring that BioMark's technological foundation is built upon peer-reviewed, world-class scientific inquiry.
お知らせ • Jan 01Biomark Diagnostics Inc. Appoints James Lavender as Board of Director, Effective December 22, 2025BioMark Diagnostics Inc. has appointed Mr. James Lavender to its Board of Directors following resolutions from the Annual General Meeting held on December 22, 2025. Mr. Lavender and his group were major investors in BioMark's most recent financing, completed in March 2025, underscoring strong insider alignment with the Company's growth strategy as it transitions from development to commercial execution. As BioMark accelerates its U.S. market entry, Mr. Lavender has been instrumental in opening high-level channels with state-level organizations and strategic investment groups across the United States. Mr. Lavender brings extensive software development and enterprise sales experience from leading technology companies, with a particular focus on scaling data-driven platforms. He has been a key advocate for expanding BioMark's use of Artificial Intelligence (AI) and Machine Learning (ML) to enhance clinical performance, automation, and scalability of metabolomics-based oncology diagnostics.
お知らせ • Oct 14Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025.
お知らせ • May 12Biomark Diagnostics Inc. Announces the Publication of Pivotal Study as Part of the Special Issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular SciencesBioMark Diagnostics Inc. announced the publication of a pivotal study as part of the special issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular Sciences. The research, titled "Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection", provides significant external validation for BioMark's metabolomics and machine learning powered technology, particularly highlighting its high specificity and accuracy in detecting early-stage non-small cell lung cancer (NSCLC) and differentiating it from other non-cancerous lung conditions. The study utilized a large, clinically diverse patient cohort, analyzing 680 archived plasma samples in a discovery cohort and an independent set of 216 plasma samples for validation. A key strength of the research was the composition of the control group, which included not only healthy individuals but also patients with various non-cancerous lung diseases. This design allowed for a rigorous assessment of the test's ability to accurately identify lung cancer, minimizing the potential for false positives due to other lung conditions. The ability to detect lung cancer at its earliest stages significantly improves patient outcomes and survival rates. Current screening methods, such as low dose computed tomography (LDCT), have limitations, including lower sensitivity and specificity compared to regular CT scans, and can result in false positives leading to unnecessary invasive procedures. BioMark's minimally invasive blood test offers a promising approach to complement current screening methods, potentially leading to earlier interventions and better patient prognoses.
お知らせ • Mar 31Biomark Diagnostics Inc. announced that it has received CAD 4.261195 million in fundingOn March 31, 2025, BioMark Diagnostics Inc. closed the transaction. The company announced that it has issued 4,593,984 units at an issue price of CAD 0.30 per unit for gross proceeds of CAD 1,378,195.2 in second and final tranche. The Units were issued at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 4,261,195. Each unit consists of one common share and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. Certain Insiders, Directors and Officers subscribed for a portion of this placement. Participation of the insiders of the Company in the private placement. The transaction included participation from United States and Europe. The transaction is oversubscribed.
お知らせ • Mar 27Biomark Diagnostics Inc. announced a financing transactionBiomark Diagnostics Inc. announced a non-brokered private placement that it will issue units to receive funding on March 26, 2025. Each unit consists of one common share of company and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. No finders' fees were payable on the private placement. Under the first tranche, the company issued 9,610,000 units at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 2,883,000.
お知らせ • Oct 21Biomark Diagnostics Inc., Annual General Meeting, Dec 27, 2024Biomark Diagnostics Inc., Annual General Meeting, Dec 27, 2024. Location: british columbia, richmond Canada
お知らせ • Sep 10Biomark Diagnostics Completes Testing of over 5,400 Subjects as Part of A Validation Study for Early Lung Cancer DetectionBioMark Diagnostics Inc. announced the successful completion of a significant clinical trial in collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Quebec. Over 5,400 patient samples were analyzed using BioMark's innovative lung cancer assay, demonstrating the test's potential to revolutionize early detection and improve patient outcomes. BioMark has partnered with a leading data analytics group possessing robust artificial intelligence and machine learning capabilities to analyze the vast amount of data collected during the trial. The results of the study will be presented at an upcoming medical conference and submitted for publication in a peer-reviewed journal. BioMark is committed to advancing the development of its lung cancer assay and making it available to patients in need as soon as possible. This innovative technology has the potential to significantly improve early detection rates and treatment outcomes for this devastating disease.
お知らせ • Dec 29Biomark Diagnostics Inc. announced that it has received CAD 1.9 million in fundingBiomark Diagnostics Inc announced that it has completed a non-brokered private placement of 7,600,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 1,900,000 on December 29, 2023. The securities issued under the private placement will be subject to a hold period of four months and one day. Each unit consists of one common share and one-full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.45 per share for a period of three years from the closing date of the private placement, subject to an acceleration clause. Certain Insiders, Directors and Officers subscribed for a portion of this placement. No Finders' fees were payable on the private placement.
お知らせ • Oct 13Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2023Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2023.
お知らせ • Jan 12BioMark Diagnostics Inc. Announces Update from Ongoing Clinical Trial Using its Lung Cancer Liquid Biopsy Test as it Prepares for Commercial LaunchBioMark Diagnostics Inc. announced several updates from ongoing clinical trial using the Company's liquid biopsy test for early cancer detection and monitoring of lung cancer. As clinical trial success relies on effective patient recruitment, BioMark is delighted to announce that enrollment for its pivotal lung cancer screening study exceeded 1,000 participants in less than one year. The lung cancer screening demonstration project led by Dr. Simon Martel, pulmonologist at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie de Québec- Université Laval - IUCPQ-UL), is intended to combine BioMark's metabolomics liquid biopsy test with radiomics and genetics biomarkers to help at-risk Quebecers get access to an accurate and accessible lung cancer screening program. The multimodal study was designed to recruit 4,000 participants from eight major hospitals across in Quebec, generating data that can support BioMark's implementation within the Province of Quebec. The Company also announces its first international patient recruited as part of a European prospective lung cancer screening trial in France known as the ILYAD study. BioMark's blood-based biomarker panel has been selected to define personalized lung cancer risk assessment in Europe's screen-eligible population who are most likely to benefit from a CT scan. The study is being conducted by Pr Sébastien Couraud, pulmonologist at the Hospices Civils de Lyon (HCL) and through a partnership with France- based TransDiag. Through the ILYAD study, the investigators are studying the participation rate during the initial round in the lung cancer screening program and assessing the performance of several blood- based biomarkers for the detection of cancers in screened individuals. The test being developed by the consortium would offer the opportunity to screen nearly 4 million individuals in France who are eligible for lung cancer screening under current European guidelines. These at-risk individuals are aged between 50 and 75 and have a history of heavy smoking. The Company intends to pursue clinical validation of the test as a laboratory developed test (LDT) in parallel with these ongoing studies. The BioMark Lung Cancer Risk Assessment Test will be available through its Quebec-based accredited laboratory, BioMark Diagnostic Solutions Inc., within approximately 9 - 12 months based on the completion of the ISO 15-189 certification.